Industry

ZUG, Switzerland–(BUSINESS WIRE)–Galderma: Continued strong commercial and financial performance in a resilient market Galderma delivered continued strong growth across product categories, with net sales up 15% year-on-year on a constant currency basis at 1,914 M USD Particularly strong performance of Injectable Aesthetics and Dermo-cosmetics product categories with growth of 32% and 31% on a constant … [Read more…]

BEIJING & DARMSTADT, Germany–(BUSINESS WIRE)–#License–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) entered into a global licensing agreement with Merck for the use of Biocytogen’s RenMice™ platform. Under the terms of the agreement, Merck will have full access to Biocytogen’s RenMice™ platform to discover and develop fully human antibody therapeutics for an unlimited number of drug targets. … [Read more…]

First European Commission approval of a bispecific antibody discovered using OmniAb OmniAb, Inc. is eligible to receive a $10 million milestone upon first commercial sale in Europe EMERYVILLE, Calif.–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the Janssen Biotech, Inc. (Janssen) received conditional marketing authorization (CMA) from the European Commission for TECVAYLI® (teclistamab) as monotherapy … [Read more…]

TEANECK, N.J.–(BUSINESS WIRE)–Phibro Animal Health Corporation (Nasdaq:PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2022, and provided financial guidance for the year ending June 30, 2023. Highlights for the three months ended June 30, 2022 (compared to the three months ended June 30, 2021) … [Read more…]

HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences: Citi 17th Annual BioPharma Conference Date: Wednesday, September 7th, 2022 Location: Boston, MA Format: 1-on-1 meetings only Morgan Stanley 20th … [Read more…]

– Dr. Sigal Brings Decades of Leadership Experience at Biopharmaceutical Companies – – Served as Chief Scientific Officer and a Director of Bristol-Myers Squibb – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Elliott Sigal, M.D., Ph.D., to its Board of Directors. Dr. Sigal brings decades … [Read more…]

Now Through September 6, Customers Can Support City of Hope’s Pediatric Cancer Program at all Smart & Final Locations LOS ANGELES–(BUSINESS WIRE)–#MySmartandFinal—Smart & Final, the smaller, faster grocery warehouse store for household and business customers, is holding its annual fundraiser benefiting City of Hope’s Kids 4 Hope program. A world-renowned independent research center, City of … [Read more…]

LAGUNA HILLS, Calif. & ORANGE COUNTY, Calif.–(BUSINESS WIRE)–#AcuteRecoveryCare—Pop-in Care, a Parentis Health subsidiary company, has introduced a new pricing structure for its licensed in-home care services catering to individuals with disabilities, the elderly, and those recovering from surgeries or other acute illnesses. Pop-in Care continues to maintain its emphasis on short visits, without minimum hourly … [Read more…]

Fully Customized Lineup of In-the-Ear Hearing Aid Solutions Designed for a Discreet & Personalized Listening Experience SOMERSET, N.J.–(BUSINESS WIRE)–#Oticon–Hearing aid manufacturer Oticon, Inc. is launching Oticon Own™, a new family of custom hearing aids. Developed for ultimate discreetness and superior sound quality, Oticon Own is a fully customized in-the-ear hearing solution. Harnessing the power of … [Read more…]

BEIJING & BURLINGTON, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc. (“CANbridge,” 1228.HK), a China and U.S.-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, today announced financial results for the six months ended 2022 and a corporate update. “We have made significant progress over the first half … [Read more…]